- Home
- OTLK vs BRT Comparison
OTLK vs BRT Comparison
Compare OTLK & BRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OTLK | BRT |
|---|---|---|
| Founded | 2010 | 1972 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 249.6M | 271.2M |
| IPO Year | 2016 | 1994 |
Fundamental Metrics
Financial Performance| Metric | OTLK | BRT |
|---|---|---|
| Price | $0.66 | $14.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | $2.50 | ★ $19.75 |
| AVG Volume (30 Days) | ★ 21.2M | 31.3K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | ★ 7.03% |
| EPS Growth | ★ 55.91 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $8,146,123.00 | ★ $97,028,000.00 |
| Revenue This Year | $1,430.98 | $3.82 |
| Revenue Next Year | $173.23 | $5.35 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1.46 |
| 52 Week Low | $0.16 | $13.18 |
| 52 Week High | $2.54 | $16.69 |
Technical Indicators
Market Signals| Indicator | OTLK | BRT |
|---|---|---|
| Relative Strength Index (RSI) | 37.15 | 41.27 |
| Support Level | $0.60 | $13.18 |
| Resistance Level | $0.94 | $14.94 |
| Average True Range (ATR) | 0.04 | 0.33 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 53.36 | 9.82 |
Price Performance
Historical ComparisonAbout OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About BRT BRT Apartments Corp. (MD)
BRT Apartments Corp is a real estate investment trust company. The company is focused on the ownership, operation, and development of multi-family properties. BRT also owns and operates other real estate assets. All of the Company's assets are comprised of multi-family real estate assets generally leased to tenants on a one-year basis.